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Will Gene Patents Impede Whole Genome Sequencing?: 
Deconstructing the Myth that 20% of the 
Human Genome Is Patented
Christopher M. Holman*
During oral arguments before the Court of Appeals of the Federal Circuit in Association 
IRU0ROHFXODU3DWKRORJ\Y863DWHQWDQG7UDGHPDUN2IÀFH (AMP v. PTODKLJKSURÀOH
lawsuit challenging the validity of so-called “gene patents,” Judge Bryson asked the attor-
QH\UHSUHVHQWLQJ0\ULDG*HQHWLFVRZQHURIWKHVSHFLÀFSDWHQWVXQGHUDWWDFNZKHWKHUWKH
company’s patents would be infringed by the sequencing of an individual’s genome.1 The at-
torney did not seem to have previously considered the question, but ventured that in his view 
whole genome sequencing (WGS) would not constitute infringement because Myriad’s pat-
ent claims are directed towards isolated genes, not the entire chromosome.2 Later during the 
proceedings, the ACLU attorney representing the plaintiffs begged to differ, offering up his 
opinion that Myriad’s gene patents, particularly claims directed to “isolated DNA that codes 
for the BRCA polypeptide,” would in fact be infringed by WGS.3
The question of whether Myriad’s patents would be infringed by WGS is entirely hypo-
thetical—no one has ever been sued for infringing a human gene patent based on the sequenc-
ing of an individual gene, let alone an entire genome.4 But Judge Bryson is understandably 
concerned with the policy implications of AMP v. PTODQGKLVTXHVWLRQUHÁHFWVDZLGHO\KHOG
perception that gene patents threaten to substantially impede the implementation not only of 
WGS, but of other genetic diagnostic technologies that simultaneously test for variations in 
multiple human genes.
*Associate Professor of Law, University of Missouri – Kansas City
2UDO$UJXPHQWDW$VV·QIRU0ROHFXODU3DWKRORJ\Y863DWHQW	7UDGHPDUN2IÀFH
No. 2010-1406 (Fed. Cir. July 29, 2010), available at http://www.cafc.uscourts.gov/oral-argument-
recordings/search/audio.html.
2.  Id.
3.  Id. at 34:40.
4.  See generally Christopher M. Holman, Trends in Human Gene Patent Litigation, 322 SCI. 198 
(2008) [hereinafter Holman, Trends in Human Gene Patent Litigation]; Christopher M. Holman, The 
Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litiga-
tion, 76 UMKC L. REV. 295 (2007) [hereinafter Holman, The Impact of Human Gene Patents].
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To a large extent, the fear that gene patents might prove an obstacle to WGS arises from a 
widely held belief that 20% of human genes are “patented,” and that as a consequence those 
engaged in developing and implementing WGS will be forced to either obtain licenses under 
a large number of gene patents, which would be prohibitively expensive and time-consum-
ing, or risk a substantial threat of being sued for patent infringement by a host of gene patent 
RZQHUV)RUH[DPSOH-XGJH%U\VRQVSHFLÀFDOO\LQGLFDWHGWKDWKLVLQTXLU\LQWRWKHSUHFOXVLYH
effect of gene patents on personal WGS was prompted by the concern that sequencing a per-
son’s genome might require obtaining licenses to hundreds or even a thousand gene patents.5 
The notion that access to 20% of human genes is effectively precluded by gene patents 
has become something of an urban legend, and is routinely cited as fact, often without any 
supporting reference.6 However, a review of the literature reveals that the idea stems from a 
single study by Jensen and Murray published in 2005 (referred to hereafter as “the Study”) 
which purports to map the “intellectual property landscape of the human genome.”7 In this 
article, I deconstruct the Study and explain why it in no way supports a conclusion that 20% 
of human genes are “patented,” or that WGS will result in the infringement of a plethora of 
gene patents. To the contrary, my analysis of the claims in a large sampling of the patents 
LGHQWLÀHGLQWKH6WXG\DV´JHQHSDWHQWVµLQGLFDWHVWKDWWKHIHDUWKDWJHQHSDWHQWVZLOOLPSHGH
WGS has, in all likelihood, been greatly overstated.
Deconstructing the Jensen/Murray Study
Although Jensen and Murray state in their article that “20% of human genes are explicitly 
claimed as U.S. IP,”8 their supporting online materials make clear that what they actually did 
was identify issued U.S. patents in which a human gene sequence, or the protein encoded by 
human gene sequence, was explicitly mentioned in the patent claims.9 The critical distinction 
between a gene being “claimed” versus a gene being “mentioned” in a patent claim has ap-
parently been lost on those who assume that the Study shows that 20% of human genes are 
patented. The mere fact that a patent claim mentions a gene sequence (or the protein encoded 
by it) in no way implies that the patent completely precludes access to the gene, nor does it 
warrant an assumption that sequencing the gene would result in patent infringement.
5.  Oral Argument, supra note 1, at 11:51.
6.  See, e.g., Sam Kean, The Human Genome (Patent) Project, 331 SCI. 530 (2011) (making unsup-
ported assertion that 20% of human genes are patented).
7.  Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human Genome, 310 SCI. 
239 (2005).
8.  Id. at 239.
0RUHVSHFLÀFDOO\WKH\FRQGXFWHGDQDXWRPDWHGVHDUFKWRLGHQWLI\DOO86SDWHQWVUHFLWLQJWKHFD-
nonical term “SEQ ID NO.” in the claims, and wherein the “SEQ ID NO.” term is used in conjunc-
WLRQZLWKDVSHFLÀFJHQHWLFVHTXHQFHFRUUHVSRQGLQJWRDNQRZQKXPDQJHQH.\OH-HQVHQ	)LRQD
Murray, Supporting Online Material for Intellectual Property Landscape of the Human Genome, 
SCI. (Oct. 14, 2005), http://www.sciencemag.org/cgi/data/310/5746/239/DC1/1.
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,QRUGHUWREHWWHUXQGHUVWDQGWKHDFWXDOVLJQLÀFDQFHRIWKH6WXG\DQGPRUHJHQHUDOO\WKH
potential preclusive effect of gene patents on WGS, I analyzed the claims from a random 
VDPSOLQJRIRIWKHSDWHQWVLGHQWLÀHGDV´JHQHSDWHQWVµLQWKH6WXG\10 The 533 selected 
patents span the entire temporal range of the Murray and Jensen data set, from some of the earliest 
patents, issued in 1993, to the most recent issued in 2005 (the year they conducted the Study).11 
After reviewing the patent claims, I assigned the patents to three relevant (and sometimes overlap-
ping) categories based on the nature of the subject matter encompassed by the claims.
To summarize, Category I comprises the substantial number of patents in the sampling 
that do not include a single claim that could, under any circumstance, be infringed by any 
form of genetic testing, including not only genetic testing that involves DNA sequencing, 
but more generally other methods, such as those that involve measuring gene expression by 
RNA hybridization. Category II comprises patents that include one or more product claims 
that purport to encompass a DNA molecule corresponding in sequence to at least some por-
tion of a human gene. Category III comprises patents with one or more method claims that 
appear to have at least some potential for being infringed by some form of genetic testing, 
although not necessarily by DNA sequencing. A more detailed discussion of the patents fall-
ing within the three categories is provided below.
As a preliminary matter, it is important to recognize that interpreting patent claims out-
side the context of patent infringement litigation is a notoriously unpredictable process, and 
DVDSUDFWLFDOPDWWHULWLVJHQHUDOO\LPSRVVLEOHWRGHÀQLWLYHO\VWDWHWKHSUHFLVHVFRSHRIWKH
subject matter covered by the claims in these patents. The vagaries of claim interpretation 
KDYHEHHQZHOOGRFXPHQWHGDQGDUHUHÁHFWHGLQWKHKLJKUDWHDWZKLFKWKH&RXUWRI$SSHDOV
of the Federal Circuit reverses the claim interpretation rulings of district courts (and it is not 
uncommon for the Federal Circuit judges to disagree amongst themselves as to the proper in-
terpretation of a claim).12,QGHHGWKHDPELJXLW\RIWKHVFRSHRIFRYHUDJHGHÀQHGE\DSDWHQW
has led some, including at times the Federal Trade Commission, to characterize patents as 
nothing more than “probabilistic” property rights.13 The uncertainty is especially pronounced 
.\OH-HQVHQJHQHURXVO\SURYLGHGPHZLWKDVSUHDGVKHHWOLVWLQJDOORIWKHSDWHQWVLGHQWLÀHG
in their study, and granted me permission to post the data on the Internet. It is available through 
Google documents at https://spreadsheets.google.com/spreadsheet/ccc?key=0At_llJGo9WK0dG00
dUh4WXlNcm5UeFpKcTNtMEhraVE&hl=en_US.
7KHVXSSRUWLQJRQOLQHPDWHULDOVIRUWKLVDUWLFOHSURYLGHWKHHQWLUHOLVWRISDWHQWVLGHQWLÀHGLQWKH
6WXG\DVZHOODVDOLVWRIWKHSDWHQWV,VSHFLÀFDOO\DQDO\]HG7KHVDPSOLQJH[FOXGHVSDWHQWVDV-
signed to Incyte, which were studied separately, as discussed below.
12.  See David L. Schwartz, Practice Makes Perfect? An Empirical Study of Claim Construction 
Reversal Rates in Patent Cases, 107 MICH. L. REV. 223 (2008); Phillips v. AWH Corp., 415 F.3d 
1303 (Fed. Cir. 2005) (en banc).
13.  Petition for Writ of Certiorari at 16-17, FTC v. Schering-Plough Corp., 126 S. Ct. 2929 (2006) 
(No. 05-273) (citing Mark A. Lemley & Carl Shapiro, Probabilistic Patents, J. ECON. PERSP., Spring 
2005, at 75), available at http://www.ftc.gov/os/2005/08/050829scheringploughpet.pdf; see also 
Christopher M. Holman, Do Reverse Payment Settlements Violate The Antitrust Laws?, 23 SANTA 
CLARA COMPUTER & HIGH TECH. L.J. 489, 532-33 (2007).
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with respect to gene patents, which have rarely been litigated, particularly in the context of 
genetic testing. As a consequence, there is little guidance to be found in the case law.14 This 
explains why Judge Bryson was unsure whether individual WGS would infringe Myriad’s 
claims, and the two attorneys could plausibly give diametrically opposite answers—in fact, 
nobody knows for sure.
 Nonetheless, the scope of patent claims is delimited by their text, and language used to 
claim an invention can only be stretched so far. As explained below, it is clear from a facial 
UHDGLQJRIWKHFODLPVWKDWPDQ\RIWKH´JHQHSDWHQWVµLGHQWLÀHGLQWKH6WXG\ZRXOGQRWEH
infringed by DNA sequencing under any plausible interpretation. In fact, while some of the 
patents might be deemed infringed by some forms of DNA sequencing, there is reason to 
believe that few if any of the patents analyzed include claims that a court would necessarily 
ÀQGYDOLGDQGLQIULQJHGE\DOOIRUPVRI'1$VHTXHQFLQJ0RGHVRIVHTXHQFLQJWKDWGRQRW
UHTXLUH'1$DPSOLÀFDWLRQRUV\QWKHVLVVXFKDVUHFHQWO\GHYHORSHGQDQRSRUHVHTXHQFLQJ
technologies, are particularly likely to avoid infringement.15
Category I: Patents That Would Clearly Not Be Infringed by Genetic Testing
One hundred forty of the 533 patents in the sampling fall into Category I, including 96 that 
should not be characterized as “gene patents” under even the most expansive interpretation 
of this amorphous but widely used nomenclature. These patents are directed primarily to-
ZDUGVSURWHLQVDQGPHWKRGVRIXVLQJSURWHLQVDQGZHUHVSXULRXVO\LGHQWLÀHGDVJHQHSDWHQWV
by the methodology employed in the Study because the amino acid sequence of the protein 
was referenced in the claim by a “SEQ ID NO.” that also happened to be associated with the 
gene encoding the protein.16 
Category I also includes 44 patents that mention DNA sequences, and thus might plausi-
bly be characterized as gene patents, but that clearly would not be infringed by any form of 
JHQHWLFWHVWLQJ6RPHRIWKHVHSDWHQWVZHUHÁDJJHGLQWKH6WXG\EHFDXVHWKH\KDYHFODLPV
GLUHFWHGWRZDUGVFHOOVRURUJDQLVPVWKDWKDYHEHHQJHQHWLFDOO\PRGLÀHGE\WKHLQWURGXFWLRQ
14.  See Holman, Trends in Human Gene Patent Litigation, supra note 4; Holman, The Impact of 
Human Gene Patents, supra note 4. 
15.  W. Nicholson Price II, Unblocked Future: Why Gene Patents Won’t Hinder Whole-Genome Se-
quencing and Personalized Medicine, 33 CARDOZO L. REV. (forthcoming 2012), available at http://
ssrn.com/abstract=1914560.
16.  Since 1990, the PTO has required patent applicants to identify most protein and DNA sequenc-
es by means of a sequence ID number, using the canonical term “SEQ ID NO.” The Study identi-
ÀHGSDWHQWVKDYLQJFODLPVWKDWLQFOXGHWKHWHUP´6(4,'12µDQGZKHUHLQWKH6(4,'12ZDV
associated with a known human gene. However, sometimes the same SEQ ID NO is used to refer 
not only to the gene sequence, but also the amino acid sequence of the protein encoded by the gene, 
ZKLFKOHGWRWKHVHVSXULRXVKLWV$QH[DPSOHRIDSDWHQWPLVLGHQWLÀHGDVDJHQHSDWHQWLQWKH6WXG\
owing to a claim identifying a protein sequence by SEQ ID NO. is U.S. patent number 5,843,888 
(Claim 1: “A non-naturally occurring mutant human hemoglobin wherein the valine residue at posi-
tion 96 of the alpha chain (SEQ ID NO: 1) is replaced by a tryptophan residue.”).
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of a DNA sequence encoding a human gene.17 Others are directed towards a fusion gene 
(man-made recombinant constructs made by fusing together gene sequences in a manner that 
GRHVQRWRFFXULQQDWXUHRUDYDFFLQHRUDVSHFLÀFFRPSOH[EHWZHHQD'1$PROHFXOHDQGD
protein.186RPHRIWKHSDWHQWVLQWKLVFDWHJRU\DUHGLUHFWHGWRZDUGVVSHFLÀFPHWKRGVRIXVLQJ
RUDQDO\]LQJ'1$EXWZHUHFODVVLÀHGDVJHQHSDWHQWVVROHO\EHFDXVHWKH\LQFOXGHDGHSHQ-
GHQWFODLPFRYHULQJXVHRIWKHPHWKRGLQFRQQHFWLRQZLWKDVSHFLÀFKXPDQJHQHVHTXHQFH19
While none of these 140 patents in Category I could be infringed by genetic testing or 
WGS, they were all tallied as gene patents in the Study. As a result, all of the genes cor-
UHVSRQGLQJWR WKH'1$DQGSURWHLQVHTXHQFHVUHIHUHQFHGLQ WKHFODLPVZHUHFODVVLÀHGDV
“patented,” thus contributing to the myth that 20% of human genes are patented.
Category II: Patents with Product Claims Covering DNA Molecules
Three hundred sixty-six of the 533 patents fall into Category II, which comprises any pat-
ent that includes at least one product claim that covers a DNA molecule having a sequence 
that Jensen and Murray found to be associated with a naturally occurring human gene, or 
some portion thereof. These are the quintessential human gene patents that most people prob-
ably envision when they think of genes being patented, and many have apparently jumped to 
the conclusion that such patents would necessarily be infringed by any testing or use of the 
“claimed” gene.20 But this is an unwarranted assumption. These patents claim molecules, not 
genes per se, and would only be infringed by a DNA sequencing methodology that necessar-
LO\HQWDLOV´PDNLQJRUXVLQJµWKH'1$PROHFXOHGHÀQHGE\WKHFODLP21
For example, claims to DNA molecules having the sequence of a naturally occurring hu-
PDQJHQHDUHDOPRVWLQYDULDEO\OLPLWHGWRIRUPVRIWKH'1$WKDWDUHLVRODWHGSXULÀHGDQGRU
recombinant (of these limitations, “isolated” appears to be by far the most commonly used). 
17.  See, e.g., U.S. Patent Nos. 5,861,310 and 5,932,780.
18.  See, e.g., U.S. Patent Nos. 5,712,121; 6,537,594; and 5,670,621.
19.  See, e.g., U.S. Patent No. 5,821,089 (Claim 1: “A method of incorporating an amino acid 
analog into at least one polypeptide produced by a cell selected from the group consisting of pro-
karyotic cell and eukaryotic cell comprising: providing a cell selected from the group consisting of 
a prokaryotic cell and eukaryotic cell; providing hypertonic growth media containing at least one 
amino acid analog selected from the group consisting of trans-4-hydroxyproline and 3-hydroxypro-
line; and contacting the cell with the growth media wherein the at least one amino acid analog is 
assimilated into the cell and incorporated into at least one polypeptide.”).
20.  See, e.g., 6WLÁLQJRU6WLPXODWLQJ³7KH5ROHRI*HQH3DWHQWVLQ5HVHDUFKDQG*HQHWLF7HVWLQJ
Hearing Before the Subcomm. on Courts, the Internet, and Intellectual Prop. of the H. Comm. on 
the Judiciary, 110th Cong. 38-41 (Oct. 30, 2007) (statement of Dr. Mark Grodman, CEO of Bio-
Reference Laboratories, Inc.), available at http://judiciary.house.gov/hearings/pdf/Grodman071030.
pdf.
21.  Christopher M. Holman, *HQH3DWHQWV8QGHU)LUH:HLJKLQJWKH&RVWVDQG%HQHÀWV, in BIO-
TECHNOLOGY AND SOFTWARE PATENT LAW: A COMPARATIVE REVIEW OF NEW DEVELOPMENTS (Emanuela 
Arezzo & Gustavo Ghidini eds., forthcoming 2011).
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The inclusion of these limitations is critical—it is generally accepted that a DNA molecule 
cannot be claimed in a manner that would cover the molecule as it exists in nature, e.g., as a 
gene residing in its normal location on a human chromosome.22 DNA sequencing will only 
constitute infringement of a claim to an isolated DNA molecule if the sequencing meth-
RGRORJ\LQYROYHVWKHLVRODWLRQRIWKHHQWLUH'1$PROHFXOHDVGHÀQHGE\WKHFODLP7RP\
knowledge, after extensive research, no court has ever interpreted a claim to an isolated or 
SXULÀHG'1$PROHFXOHVREURDGO\DQGVXFKDFODLPKDVQHYHUEHHQIRXQGLQIULQJHGE\'1$
sequencing. In fact, there are judicial decisions that, while not directly on point, suggest that 
a court might very well interpret a claim to isolated DNA in a relatively narrow manner such 
that it would not be infringed by at least some forms of DNA sequencing, particularly certain 
QH[WJHQHUDWLRQWHFKQRORJLHVWKDWGRQRWUHTXLUHWKHDPSOLÀFDWLRQRI'1$23
In normal parlance, isolation of a naturally occurring molecule arguably implies not only 
separating it from its native context, but doing so in a manner that results in some sort of 
stable preparation in which the isolated molecule is known to be present, and thus available for 
retrieval and further processing or use at a later time. In the judicial decisions that are convention-
ally cited for the proposition that isolated biomolecules are patentable, the patent was invariably 
based on the inventor’s successful development of a stable preparation comprising the isolated 
biomolecule.24 Gene patents claiming isolated DNA molecules are generally based on the physical 
isolation of the DNA molecule in a form that can be accessed for further processing or study.
A Dutch court recently took this approach in interpreting a claim broadly reciting an iso-
lated gene, rejecting the patent owner’s argument that the claim encompasses any DNA 
sequence removed from its natural environment, and concluding that “the average person 
skilled in the art would understand the term isolated DNA as DNA that has been retrieved from the 
cell (core) of an organism for further treatment in a manner as is usual in the relevant profession.”25 
Based on this interpretation, this gene patent claim was found not to be infringed, illustrating that 
gene patents do not necessarily cover all recombinant uses of the claimed gene.26
22.  Utility Examination Guidelines, 66 Fed. Reg. 1092 (January 5, 2001).
23.  See, e.g., Synaptic Pharm. Corp. v. MDS Panlabs, Inc., 265 F. Supp. 2d 452 (D.N.J. 2002).
3DUNH'DYLV	&RY+.0XOIRUG&R)6'1<SXULÀHGDGUHQDOLQH
for use as drug held patentable); In re Bergstrom, 427 F.2d 1394, 1397, 166 (C.C.P.A. 1970) (pros-
taglandin from human prostate gland isolated in pure crystalline form held patentable).
25.  Monsanto Tech. LLC v. Cefetra B.V., No. 249983/ HA ZA 05-2885, at ¶4.3 (Hague Dist. Ct. 
2008) (Neth.), translation at http://holmancm.googlepages.com/CefetraEUBiotechDirective.pdf; 
see also Case C-428/08, Monsanto Tech. LLC v. Cefetra BV (E.C.J. July 6, 2010), http://eur-lex.
europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:62008CJ0428:EN:HTML; Chris Holman, Mon-
santo v. Cefetra: EU Court of Justice Limits Scope of Patent Protection Available to Gene Sequenc-
es, HOLMAN’S BIOTECH IP BLOG (July 9, 2010), http://holmansbiotechipblog.blogspot.com/2010/07/
monsanto-v-cefetra-eu-court-of-justice.html. 
26.  See also Christopher M. Holman, Learning from Litigation: What Can Lawsuits Teach Us 
About the Role of Human Gene Patents in Research and Innovation?, 18 KAN. J.L. & PUB. POL’Y 
215 (2009) (identifying multiple instances wherein an asserted human gene patent was found not to 
have been infringed).
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If a court were to interpret a limitation such as “isolated” in this relatively narrow man-
ner, it seems doubtful that all forms of DNA sequencing would be found infringing. Large-scale 
DNA sequencing methodologies, such as those that would be applied to the sequencing of entire 
JHQRPHVJHQHUDOO\GRQRWUHTXLUHWKH´ LVRODWLRQµRIGHÀQHGSUHSDUDWLRQVRI'1$7KLVLVSDUWLFX-
larly the case with respect to some of the next-generation sequencing technologies. For example, 
WKH3DFLÀF%LRVFLHQFHVJHQHVHTXHQFLQJWHFKQRORJ\UHOLHVRQWKHREVHUYDWLRQRI'1$V\QWKHVLVDV
LWRFFXUVRQDQLPPRELOL]HG'1$SRO\PHUDVHWKXVUHTXLULQJQRGLVFHUQLEOHLVRODWLRQRIGHÀQHG
DNA molecules.27 It is far from clear that the transient “isolation” that might occur during the 
FRXUVHRIVHTXHQFLQJYLDWKH3DFLÀF%LRVFLHQFH·VWHFKQRORJ\RUE\PHDQVRIRWKHUQH[WJHQHUDWLRQ
sequencing technologies such as nanopore technology,28ZRXOGVXIÀFHWRHVWDEOLVKLQIULQJHPHQW
In order for all modes of DNA sequencing to result in infringement of claims to isolated 
DNA molecules, the term “isolated” would have to be given a very broad interpretation, so as to 
basically encompass any form of DNA existing in a form distinct from its native environment. The 
Dutch court mentioned above rejected such a broad interpretation, but that does not mean that a 
U.S. court might not reach a different outcome, at least with respect to some claims directed 
to isolated DNA molecules. In fact, the district court in AMP v. PTO adopted a very broad interpre-
WDWLRQIRU´ LVRODWHGµLQWKH0\ULDGSDWHQWFODLPVDSSDUHQWO\EDVHGRQDGHÀQLWLRQRIWKHWHUPLQWKH
FRUUHVSRQGLQJSDWHQWVSHFLÀFDWLRQV29 But the court appears to have devoted little attention to that 
SDUWLFXODULVVXHDQGLWLVKDUGWRVD\ZKHWKHUWKLVGHÀQLWLRQZRXOGVWDQGLIFKDOOHQJHGRQDSSHDO
Moreover, it does not necessarily mean that such a broad interpretation of “isolated” would be 
DSSOLHGWR'1$FODLPVLQJHQHUDOSDUWLFXODUO\LQGLIIHUHQWSDWHQWVLQZKLFKWKHVSHFLÀFDWLRQ
GHÀQHVWKHWHUP´LVRODWHGµPRUHQDUURZO\HLWKHUH[SOLFLWO\RULPSOLFLWO\
In any event, a broad interpretation of a term such as “isolated” could be a double-edged 
sword. In general, the broader a claim is interpreted the more likely it is to be invalidated by 
a court during litigation, for failure to comply with one or more requirements of patent-
ability.30 For example, in order to be patentable a claimed invention must be novel and 
nonobvious. The actual legal analysis would be quite complex, but the fundamental 
principle is straightforward: in general, subject matter that would infringe a patent claim 
after the patent issues will invalidate the patent if it occurred prior to the date of invention.
This implies that a claim reciting isolated, naturally occurring DNA, if interpreted very 
broadly, might prove vulnerable to invalidation based on activities that occurred prior to 
27.  SMRTTM Technology, PAC. BIOSCIENCES OF CAL.KWWSZZZSDFLÀFELRVFLHQFHVFRPVPUWELROR-
gy/smrt-technology?page=1.
28.  Price, supra note 15.
$VV·QIRU0ROHFXODU3DWKRORJ\Y863DWHQW	7UDGHPDUN2IÀFH)6XSSG
(S.D.N.Y. 2010).
30.  F. Scott Kieff, Patents for Environmentalists, 9 WASH U. J.L. & POL’Y 307, 310-11 (2002) (ex-
plaining Judge Giles S. Rich’s famous statement that “the stronger a patent the weaker it is and the 
weaker a patent the stronger it is”).
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the patent, such as electrophoretic separation of genomic DNA fragments (e.g., in Southern 
blotting), or the creation of genomic DNA libraries in vectors such as cosmids. Both of these 
WHFKQLTXHVZHUHZLGHO\XVHGDQGUHSRUWHGORQJEHIRUHDQ\RIWKHVHJHQHSDWHQWVZHUHÀOHG
and inherently involve the isolation of large fragments of genomic DNA from their native 
environment. A full-blown legal analysis is beyond the scope of this paper, but the interested 
reader is directed to some recent Federal Circuit decisions clearly establishing that prior art 
need not explicitly describe a claimed feature of an invention in order to invalidate a claim 
covering subject matter inherently described in the prior art.31 The 2005 In re Crish decision 
is particularly on point because it unambiguously establishes that a prior art reference need 
not disclose the sequence of a DNA molecule in order to invalidate by anticipation.32
A very broad interpretation of terms such as “isolated” could also raise substantial va-
lidity issues under the enablement and written description requirements.33 These doctrines 
have been increasingly invoked in recent years to prevent inventors from claiming “more 
than they invented,” especially with respect to inventions based on fundamental biological 
discoveries.34 It is quite possible that if a claim were interpreted so broadly as to cover essen-
tially any and all forms of a DNA molecule removed from its native context in the genome, 
a court would invalidate the claim under one of these doctrines.
Furthermore, even if a mode of DNA sequencing were found to necessarily entail the 
´LVRODWLRQµDVWKDWWHUPLVGHÀQHGE\DFRXUWRIDFODLPHG'1$PROHFXOHWKHUHDUHRWK-
er limitations in many gene patent claims that would appear to preclude infringement by 
DNA sequencing. For example, many of the patents only include claims covering an isolated 
cDNA molecule encoding a full-length protein. Most genomic genes include introns (DNA 
sequences that do not encode part of the full-length protein), which would be present in any 
isolated DNA arising in the course of sequencing a human genome but which are absent 
from isolated cDNA. Consequently, an isolated DNA arising in the course of sequencing 
a human genome would avoid infringement of claims limited to full-length cDNA. My re-
view of hundreds of gene patents indicates that most gene patents are based on the isolation 
and sequencing of cDNA, rather than genomic DNA, and thus should not be interpreted so 
broadly as to cover genomic DNA. The U.S. government apparently shares this view—dur-
ing arguments before the Federal Circuit in AMP v. PTO an attorney representing the U.S. 
government stated that a “vast majority” of the claims to isolated DNA that have been issued 
31.  Cases applying the doctrine of “inherent anticipation” include In re Cruciferous Sprout Litiga-
tion, 301 F.3d 1343 (Fed. Cir. 2002), Schering Corp. v. Geneva Pharms., Inc., 339 F.3d 1373 (Fed. 
Cir. 2003), and SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331 (Fed. Cir. 2005).
,QUH&ULVK)G)HG&LUÀQGLQJSDWHQWFODLPLQYDOLGIRUODFNRIQRYHOW\
even though prior art did not disclose sequence of claimed DNA).
33.  The statutory basis for the enablement and written description requirements is 35 U.S.C. § 112 
(2006).
34.  Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200 (Fed. Cir. 1991); Ariad Pharms., Inc. v. Eli 
Lilly & Co., 560 F.3d 1366 (Fed. Cir. 2009).
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by the PTO are to “cDNA, recombinant DNA, process claims and the like,” and therefore 
would not cover genomic DNA (and thus, by implication, genome sequencing).35
In a large number of Category II patents, the DNA product claims only cover DNA encod-
ing a full-length protein. Proteins are generally at least 100 (and typically several hundred or 
more) amino acids in length, which means that the claims would only cover DNA molecules 
at least 300 bases in length (and more often much longer). In practice, gene sequencing 
typically does not involve isolating the full-length gene as a single molecule, because only 
fragments of the full-length gene are physically sequenced. The sequence of the full-length 
gene is then determined by piecing together the sequence information for the fragments. 
)RUH[DPSOHDV5REHUW&RRN'HHJDQDQG,SRLQWHGRXWLQDQDPLFXVEULHIÀOHGLQAMP v. PTO, 
conventional BRCA genetic testing involves amplifying and sequencing fragments of the full-
length gene (amplicons), and hence does not appear to infringe Myriad’s patent claims that only 
cover DNA encoding the full-length BRCA protein.36 Large-scale DNA sequencing protocols (of 
the type that would be used for WGS) can involve relatively short sequencing reads, which would 
only necessitate the isolation of relatively short fragments of genomic DNA, irrespective of how 
broadly the term “isolated” is interpreted. This is yet another reason to conclude that at least 
some forms of genomic DNA sequencing would not infringe many Category II patents.
On their face, the broadest Category II claims would appear to be those that explicitly 
claim any polynucleotide comprising a fragment of a gene sequence. These claims often 
purport to cover not only the isolated fragment, but any isolated DNA molecule that includes 
within its sequence the claim fragment, such as a larger fragment, the full-length genomic 
DNA, or even potentially a large stretch of genomic DNA encompassing the gene. In some cases, 
the fragments are relatively long, extending many hundreds of bases and thus not likely to be in-
fringed by DNA sequencing of relatively short fragments of genomic DNA, as discussed above in 
connection with claims directed to full-length coding sequences. However, a relatively small but 
still substantial number of Category II patents include claims directed to quite small fragments. 
For example, one of the patents purports to cover any isolated DNA molecule comprising 
any sequence of 10 or more contiguous bases appearing in the claimed gene sequence.37
If interpreted broadly, these fragment claims might cover any form of genomic DNA 
sequencing that requires the isolation of fragments of genomic DNA as short as 10 or 15 
bases in length. However, the sheer breadth of such a claim might also be its downfall—a 
recent article suggests that fragment claims of this type could be declared invalid based 
on anticipation by a large number of prior art DNA sequences falling within the scope of 
35.  Oral Argument, supra note 1, at 55:00.
36.  Brief of Amici Curiae Christopher M. Holman and Robert Cook-Deegan in Support of Neither 
3DUW\$VV·QIRU0ROHFXODU3DWKRORJ\Y863DWHQW	7UDGHPDUN2IÀFH1R:/
3211513 (Fed. Cir. July 29, 2011), available atKWWSVGRFVJRRJOHFRPÀOHYLHZ"LG %BOO-*R:
K0OWVkYjg3NjItYzRjYi00ODIyLWIyMjAtYmJkZDQxMGZmYTZi&hl=en.
37.  U.S. Patent No. 5,559,023.
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the claim.38 The expansive breadth of the claim would also raise substantial issues of patent-
ability under the enablement and written description doctrines, for claiming much more than 
the inventor actually invented.
In short, it is far from certain that any Category II patents would be infringed by all modes 
of DNA sequencing, particularly next-generation technologies that arguably do not involve 
isolation of the claimed DNA molecules. For a large number of these patents, particularly 
those directed towards cDNA and full-length genes, infringement by DNA sequencing would 
appear unlikely, if not entirely out of the question.
Category III: Patents with Method Claims Potentially Infringed by Genetic Testing
&DWHJRU\ ,,,FRPSULVHV WKHSDWHQWV LGHQWLÀHG LQ WKH6WXG\ WKDW LQFOXGHRQHRUPRUH
process claims that could potentially be infringed by at least some form of genetic testing 
GHÀQHGEURDGO\WRLQFOXGHDOOIRUPVRIJHQHWLFWHVWLQJLQFOXGLQJPHWKRGRORJLHVWKDWGRQRW
involve determining the sequence of genomic DNA). There is some overlap between Category II 
and Category III—21 of the patents analyzed include claims falling into both categories. And as 
was the case with Category II, it is facially apparent that some of the Category III patents could not 
possibly be infringed by any form of genomic DNA sequencing (even though the claim might be 
infringed by some form of genetic testing that does not involve genomic DNA sequencing).39
0RVWRIWKHFODLPVLQWKH&DWHJRU\,,,LQFOXGHGVSHFLÀFWHFKQLFDOOLPLWDWLRQVWKDWZRXOG
appear to preclude infringement by at least some modes of DNA sequencing. For example, 
PDQ\RIWKHFODLPVDUHGLUHFWHGWRZDUGPHWKRGVRIWHVWLQJIRUWKHSUHVHQFHRIDVSHFLÀFJH-
netic variation in an individual, and are limited to methods that involve determining its pres-
ence by detecting hybridization to a nucleic acid or probe. It seems likely a court would interpret 
many (if not all) of these claims as limited to methods of genetic testing that involve direct detec-
tion of the hybridization event, and thus not encompassing DNA sequencing methodologies 
WKDWRQO\LQFLGHQWDOO\LQYROYH'1$K\EULGL]DWLRQHJLQWKHFRXUVHRI3&5DPSOLÀFDWLRQ40 
The term “probe” is generally used to refer to a DNA molecule that incorporates a detectable 
ODEHOVXFKDVDUDGLRDFWLYHRUÁXRUHVFHQWJURXSZKLFKZRXOGH[FOXGHPXFKRIWKHK\EULG-
ization that occurs in the course of processing samples for DNA sequencing. Other claims in this 
FDWHJRU\VSHFLÀFDOO\UHTXLUHD3&5DPSOLÀFDWLRQVWHSLQRUGHUIRUWKHUHWREHLQIULQJHPHQWZKLFK
ZRXOGUXOHRXW'1$VHTXHQFLQJWHFKQRORJLHVWKDWGRQRWUHTXLUH3&5DPSOLÀFDWLRQVXFKDVVRPH
next-generation technologies capable of sequencing a single DNA molecule.41
38.  Thomas B. Kepler, Colin Crossman & Robert Cook-Deegan, Metastasizing Patent Claims on 
BRCA1, 95 GENOMICS 312 (2010).
39.  For example, some of the patents only include claims reciting methods of analyzing the amount 
of RNA expressed from a gene, or other relatively limited methods that would not encompass DNA 
sequencing.
40.  See, e.g., U.S. Patent Nos. 5,580,727 and 5,756,288.
41.  See, e.g., PAC. BIOSCIENCES OF CAL., supra note 27; James Clarke et al., Continuous Base Identi-
ÀFDWLRQIRU6LQJOH0ROHFXOH1DQRSRUH'1$6HTXHQFLQJ, 4 NATURE NANOTECHNOLOGY 265-70 (2009). 
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On their face, the broadest Category III patents are those with claims that purport to cover 
detection of a particular genetic variation by any means, without any explicit methodological 
OLPLWDWLRQV$UHFHQWDUWLFOHLGHQWLÀHGEURDGPHWKRGFODLPVRIWKLVW\SHDVWKHPRVWGLIÀFXOW
to design around in genetic diagnostic testing, apparently based on an assumption that they 
would necessarily be infringed by virtually any mode of diagnostic testing for the claimed 
genetic variation, regardless of the analytical technique used.42 Notably, of the 533 patents 
DQDO\]HG,RQO\IRXQGWZHOYHWKDWLQFOXGHGFODLPVRIWKLVQDWXUH7KLVÀQGLQJVXJJHVWVWKDW
WKHVHEURDGPHWKRGFODLPVZKLFKVRPHKDYHLGHQWLÀHGDVSDUWLFXODUO\SUREOHPDWLFIRUJH-
netic testing and genomic sequencing, are actually quite rare, and probably only appear in the 
relatively few instances in which, at the time the claims are drafted, the gene had been shown 
WREHGLUHFWO\FRUUHODWHGZLWKDPHGLFDOO\VLJQLÀFDQW0HQGHOLDQSKHQRW\SH
There is a good chance that a court would interpret most (if not all) of these twelve patents 
in a manner that would require not only that an alleged infringer physically determine the 
sequence of the DNA molecule, but also that the same entity analyze the resulting sequence 
data for the presence of the claims genetic variation, in order for infringement to occur. For 
example, in all but one of the twelve patents there is a clause in the claim specifying that 
WKHJHQHWLFYDULDWLRQ´LQGLFDWHVµWKHSUHVHQFHRIDPHGLFDOO\VLJQLÀFDQWSKHQRW\SHVXFKDV
for example, a lower likelihood of being diagnosed with bipolar disorder.43 In a recent case 
involving claims directed towards a method of personalized medicine, the court interpreted 
DYHU\VLPLODU´LQGLFDWHVµFODXVHDVUHTXLULQJWKDWDGRFWRUEH´ZDUQHGRUQRWLÀHGµRIWKH
relevant phenotype in order for there to be infringement.44
$VDJHQHUDOPDWWHUDÀQGLQJRILQIULQJHPHQWUHTXLUHVWKDWDOOVWHSVLQDFODLPHGSURFHVV
are performed by a single entity.45 In a situation where one entity simply sequences an in-
dividual’s genomic DNA without recognizing the presence of the genetic variation, and a 
distinct and independent entity then analyzes the resulting genetic information for the exis-
tence of the variation, it might well be the case that no party is liable for infringement. This 
would occur, for example, under a scenario where one company determines an individual’s 
JHQRPLF'1$VHTXHQFHDQGDQ LQGHSHQGHQWKHDOWKFDUHSURYLGHU LGHQWLÀHVDQ\FOLQLFDOO\
VLJQLÀFDQWJHQHWLFYDULDWLRQVWKDWPLJKWEHSUHVHQW
Only one of the twelve patents, U.S. patent number 6,432,644, has a broad method claim 
that does not include a limitation specifying that the presence of the claimed genetic varia-
WLRQ´LQGLFDWHVµDOLNHOLKRRGRIVRPHVSHFLÀFSKHQRW\SH&ODLPRIWKLVSDWHQWSXUSRUWVWR
42.  Isabelle Huys et al., Legal Uncertainty in the Area of Genetic Diagnostic Testing, 27 NATURE 
BIOTECHNOLOGY 903 (2009).
43.  U.S. Patent No. 6,458,541.
44.  Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347 (Fed. Cir. 2010), cert. 
granted, 131 S. Ct. 3027 (2011).
45.  BMC Res., Inc. v. Paymentech, L.P., 498 F.3d 1373 (Fed. Cir. 2007); Muniauction, Inc. v. 
Thomson Corp., 532 F.3d 1318 (Fed. Cir. 2008).
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claim any “method for diagnosing the presence of a polymorphism in human KCNE1 . . . 
which causes long QT syndrome wherein said method is performed by means which identify 
the presence of said polymorphism.” Claim 3 of the patent depends from Claim 1 and spe-
FLÀFDOO\UHFLWHVWKDWSUHVHQFHRIWKHSRO\PRUSKLVPLVGHWHUPLQHGE\VHTXHQFLQJWKH.&1(
JHQH,WLVLPSRVVLEOHWRVWDWHZLWKFRQÀGHQFHH[DFWO\KRZDFRXUWZRXOGLQWHUSUHWWKLVFODLP
but it seems likely that an entity that sequences the KCNE1 gene in the course of sequencing 
DQLQGLYLGXDO·VJHQRPHEXWGRHVQRWVSHFLÀFDOO\ORRNIRUWKHSUHVHQFHRIWKHSRO\PRUSKLVP
ZKLFKZLOOLQDQ\HYHQWQRWH[LVWLQWKHPDMRULW\RILQGLYLGXDOVQRWDIÁLFWHGE\WKHGLVHDVH
and thus does not engage in any diagnosis, would not be found infringing.
Furthermore, the broader the Category III method claims are interpreted, the more vulner-
able they will be to invalidation, for reasons analogous to those discussed above in connec-
tion with broad Category II claims. The Federal Circuit recently provided an example of this 
in Billups-Rothenberg, Inc. v. Associated Regional and University Pathologists, Inc.,46 which 
WRP\NQRZOHGJHLVWKHÀUVWKXPDQJHQHSDWHQWFDVHLQYROYLQJDQDOOHJDWLRQRILQIULQJHPHQW
by genetic testing that has actually resulted in a substantive judicial decision.47 In Billups-
Rothenberg, the court found all of the asserted claims to be invalid, either because of an-
ticipation by prior art, or for violation of the written description requirement. This is a good 
H[DPSOHRIDSRLQW5REHUW&RRN'HHJDQDQG,DWWHPSWHGWRPDNHLQRXUDPLFXVEULHIÀOHGLQ
connection with AMP v. PTO—many gene patent claims relevant to genetic testing would face 
substantial validity issues if their owners ever attempt to enforce them in court.48 In order to 
cover all modes of DNA sequencing, these gene patent claims would have to be interpreted 
very broadly, making them more vulnerable to invalidation. This might be part of the reason 
why, to date, there has been so little gene patent litigation in the context of genetic testing.
As explained above, method claims that require both analysis of DNA molecules and 
analysis of DNA sequence would very likely not be infringed by an entity whose only ac-
tion is limited to analysis of DNA, such as by performing WGS, if that entity does not also 
engage in analysis of the sequence. By the same token, an entity such as a doctor or genetic 
counselor who only analyzes the sequence data, without physically sequencing the DNA, 
LVXQOLNHO\WREHIRXQGOLDEOHIRUSDWHQWLQIULQJHPHQW6LJQLÀFDQWO\LQDUHFHQWGHFLVLRQWKH
Federal Circuit explicitly stated that a claim purporting to cover the mere act of thinking 
about a physiological correlation would be per se patent ineligible.49 This implies that once 
an individual’s genome has been sequenced, an entity (such as a doctor or genetic counselor) 
could not be found liable for patent infringement for simply analyzing the data. In any event, 
as a practical matter it is extremely rare, if not unheard of, for a healthcare provider to be 
directly sued simply for practicing medicine.
46.  642 F.3d 1031 (Fed. Cir. 2011).
47.  Holman, Trends in Human Gene Patent Litigation, supra note 4, at 198-99; Holman, The Im-
pact of Human Gene Patents, supra note 4. 
48.  Brief of Amici Curiae Christopher M. Holman and Robert Cook-Deegan, supra note 36.
49.  Prometheus Labs., 628 F.3d at 1358.
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As DNA sequencing technology advances, it seems inevitable that an increasing number 
of individuals will obtain their own genome sequences. My research has led me to conclude 
WKDWKXPDQJHQHSDWHQWVZLOO LQDOO OLNHOLKRRGQRWSURYHDVLJQLÀFDQW LPSHGLPHQW WR WKH
widespread commercialization and utilization of WGS in the United States. However, if 
I am wrong, there are mechanisms available for circumventing U.S. patents that could be 
implemented, such as having DNA sequencing performed outside the United States, or per-
haps even on an Indian reservation.50 Once an individual obtains their own personal genome 
sequence, it does not appear that patents will pose any obstacle to having the sequence in-
formation analyzed. For example, a recent publication reported that with genomic sequence 
data in hand, one would be able to analyze for BRCA mutations without infringing any 
patent.516LJQLÀFDQWO\WKH)HGHUDO&LUFXLWKDVXQDPELJXRXVO\KHOGWKDWLPSRUWDWLRQRIGDWD
generated by a patented method does not constitute an infringement, so sequence data gener-
ated outside the United States could be imported for use and analysis in the United States.52
The Jensen & Murray Study Provides No Quantitative Measure of the Extent to 
Which Genetic Testing Would Infringe Gene Patents
At this point it should be quite apparent that the Study provides absolutely no basis to infer 
WKDWRUIRUWKDWPDWWHUDQ\GHÀQHGSHUFHQWDJHRIKXPDQJHQHVDUHFRYHUHGE\SDWHQWV
that would be infringed by sequencing, studying, or using the gene. To further illustrate this 
SRLQWQRWHWKDWVRPHRIWKHJHQHSDWHQWVLGHQWLÀHGLQWKHVWXG\DUHGLUHFWHGWRZDUGV'1$
microarrays, which simultaneously employ DNA fragments representing many hundreds or 
even thousands of distinct human genes.53 For example, Claim 1 of U.S. patent number 
6,500,938 claims “A combination comprising a plurality of polynucleotide probes, wherein 
said plurality of probes are SEQ ID NOs:1-1490.”54 This patent claim does not recite any 
IXOOOHQJWKJHQHVHTXHQFHRQO\VSHFLÀFSUREHVGHULYHGIURPSRUWLRQVRIF'1$IUDJPHQWV
representing distinct human genes.
6LJQLÀFDQWO\WKHFODLPZRXOGRQO\EHLQIULQJHGE\DSURGXFWFRPSULVLQJDVSHFLÀFFRP-
bination of all 1490 unique probes, e.g., as components of a microarray. If even one of these 
probes is missing, the product would not infringe the claim. In fact, different probes capable 
of identifying the exact same genes could be used as substitutes without infringing, as long 
50.  Specialty House of Creation, Inc. v. Quapaw Tribe, No. 10-CV-00371 (N.D. Okla. Jan. 27, 
2011) (Indian tribe enjoys sovereign immunity from patent infringement suits).
51.  Steven L. Salzberg & Mihaela Pertea, Do-It-Yourself Genetic Testing, 11 GENOME BIOLOGY 404 
(2010).
52.  Bayer AG v. Housey Pharms., Inc.,340 F.3d 1367 (Fed. Cir. 2003).
53.This was explicitly pointed out by Jensen and Murray in their Supporting Online Material, 
supra note 9.
54.  For another example, see U.S. Patent No. 6,607,879 (Claim 1: “A composition comprising 
a plurality of cDNAs for use in detecting the altered expression of genes in an immunological 
response, wherein said plurality of cDNAs comprises SEQ ID NOs:1-1508 or the complete comple-
ments thereof.”).
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DVWKHVSHFLÀFDOO\FODLPHGSUREHVDUHQRWXVHGLQWKHVSHFLÀFFRPELQDWLRQGHÀQHGE\WKH
patent claim. It would be absurd to suggest that this patent claim confers ownership of these 
1490 genes. In particular, this patent has absolutely no implications for WGS, or for the vast 
majority of research or diagnostics uses of these genes.
Bear in mind that the Study’s conclusion that 20% of human genes are mentioned in U.S. 
patents is based entirely on the fact that the authors found 4382 human genes that were men-
tioned in patent claims (which represented about 20% of known human genes at that time). 
Thus, this single microarray claim, by virtue of the fact that it mentions probes representing 
up to 1490 human genes, could independently account for up to one third of the human genes 
LGHQWLÀHGE\-HQVHQDQG0XUUD\DV´PHQWLRQHGµLQSDWHQWFODLPV
Another factor undercutting an assumption that 20% of genes are patented is the fact that 
DODUJHSHUFHQWDJHRIWKHSDWHQWVLGHQWLÀHGLQWKH6WXG\DUHQRORQJHULQIRUFH6RPHRIWKHSDWHQWV
LGHQWLÀHGLQWKH6WXG\KDYHDOUHDG\UHDFKHGWKHHQGRIWKHVWDWXWRU\WHUP³DVRI$SULOWKH
15 oldest patents had already expired, and many more will join them over the next several years. 
In addition, as of April 2011, 30% of the remaining patents in the data set have been terminated 
because the patent owners have failed to pay the necessary fees to maintain them in force.55
The Incyte Patents 
7KH 6WXG\ LGHQWLÀHG ,QF\WH 3KDUPDFHXWLFDOV,QF\WH *HQRPLFV ´,QF\WHµ D FRPSDQ\
founded around a platform technology for identifying and sequencing cDNA molecules, as 
the top gene patent assignee. According to Jensen and Murray, Incyte’s “IP rights cover 2000 
KXPDQJHQHVµZKLFKZRXOGUHSUHVHQWFORVHWRKDOIRIWKHJHQHVLGHQWLÀHGLQWKH6WXG\DV
“explicitly claimed as U.S. IP.”56 Thus, it would be informative to look closer at these patents 
which form much of the basis for the Myth.
A search of the USPTO Public PAIR system57 conducted on April 11, 2011, showed that 
RQO\RIWKH,QF\WHSDWHQWVÁDJJHGLQWKH6WXG\DUHVWLOOLQIRUFH³WKHRWKHUVKDYHDOO
expired because of Incyte’s failure to pay the necessary maintenance fees. The claims in the 
Incyte patents are directed primarily to recombinant use of the gene for the expression of the 
encoded protein. Apparently, the main value Incyte saw in patenting genes was the potential 
WKDWVRPHGD\WKHSURWHLQHQFRGHGE\WKHJHQHPLJKWSURYHFRPPHUFLDOO\VLJQLÀFDQWVXFK
as would be the case if the protein were to be approved for use as a biologic drug. When 
this failed to materialize, they made a rational decision to forgo paying the relatively modest 
55.  Patent owners are required to pay maintenance fees periodically after the patent issues, and if 
they fail to do so the patent expires, although there are mechanisms for reviving expired patents 
in some instances where failure to pay the maintenance fee was unintentional or unavoidable. 35 
U.S.C. § 41 (2006).
56.  Jensen & Murray, supra note 7.
57.  Patent Application Information Retrieval, U.S. PATENT & TRADEMARK OFFICE, http://portal.
uspto.gov/external/portal/pair.
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maintenance fees required to keep the patents in force. This implies that Incyte concluded 
(correctly in my view) that most of its human gene patents would not cover other commer-
FLDOO\VLJQLÀFDQWXVHVRIWKHJHQHVVXFKDVGLDJQRVWLFWHVWLQJRU:*6
0\UHYLHZRIPDQ\RIWKHRWKHUJHQHSDWHQWVLGHQWLÀHGE\WKH6WXG\VXJJHVWWKDWWKLVLV
generally the case; most appear to have been written with protein production in mind, and 
very few include claims drafted in a manner likely to encompass DNA sequencing. Some of 
the owners of these patents have probably continued to maintain these patents because it is 
easier to pay the relatively nominal maintenance fees than to thoroughly assess the value of 
their patents. But because of the sheer number of gene patents owned by Incyte, the cost of 
PDLQWDLQLQJWKHPEHFDPHVLJQLÀFDQWZKLFKPLJKWH[SODLQZK\WKHFRPSDQ\KDVEHHQPXFK
more aggressive in cutting its losses than gene patent owners as a whole.
Policy Implications
A recent Science article on gene patents reported that a lawyer for a company developing 
multiplex genetic diagnostic tests initially feared that his company would need to spend $35 
million in legal fees investigating whether their technology would infringe gene patents. 
However, after he had “fully analyzed the patents on a handful of genes that [his company] 
PLJKWXVHKHZDVHQFRXUDJHGÀQGLQJSOHQW\RIURRPWRRSHUDWHµ58 His experience is very 
FRQVLVWHQWZLWKP\ÀQGLQJV³DOWKRXJKPDQ\SDWHQWVKDYH LVVXHGZLWKFODLPVPHQWLRQLQJ
human genes, in actuality few if any are likely to prove substantial impediments to WGS and 
other forms of multiplex genetic testing.
As alluded to by Judge Moore during oral arguments before the Federal Circuit in AMP v. 
PTO, a decision by the court that results in the wholesale invalidation of gene patents would 
raise serious policy concerns by disrupting the expectations of investors in biotechnology, 
who have relied upon the PTO’s long-standing practice of allowing gene patents.59 Gene 
patents have played an important role in incentivizing biotechnology investment for many 
years, and to date there appears to be no compelling evidence that they have substantially im-
peded access to genetic diagnostic testing, as noted in a recent Report commissioned by the 
Secretary of Health and Human Services.60 For example, with respect to the Myriad BRCA 
WHVWWKH5HSRUWVWDWHVWKDW´RQHVXUSULVLQJÀQGLQJIURPWKHFDVHVWXGLHVZDVWKDWWKHSHUXQLW
price of the full-sequence BRCA test, which often is cited as being priced very high, was 
actually quite comparable to the price of other full-sequence test done by polymerase chain 
UHDFWLRQ3&5DWERWKQRQSURÀWDQGIRUSURÀWWHVWLQJODERUDWRULHVµ
58.  Kean, supra note 6, at 530-31.
59.  Oral Argument, supra note 1.
60.  NAT’L INSTS. OF HEALTH, REVISED DRAFT REPORT ON GENE PATENTS AND LICENSING PRACTICES AND 
THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS (Feb. 5, 2010), available at http://oba.od.nih.gov/
oba/SACGHS/SACGHS%20Patents%20Report%20Approved%202-5-20010.pdf; see also Brief of 
Amici Curiae Christopher M. Holman and Robert Cook-Deegan, supra note 36.
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The fear that gene patents will have a substantial negative effect on genetic testing, and 
particularly WGS, has been based in large part on a greatly exaggerated perception of the 
preclusive effect of these patents in the aggregate. The widespread misinterpretation of the 
Study is a good example, with so many commentators assuming incorrectly that 20% of genes 
are patented in a manner that restricts the ability to determine the sequence of the genes or test 
for genetic variations. It would be a mistake to change patent law and policy based largely 
on the misinterpretation of empirical studies such as that conducted by Jensen and Murray, 
which sheds an interesting light on the IP landscape of the human genome, but has little to 
say with respect to the impact of gene patents on DNA sequencing and genetic testing.
